Medical oncology is the specialty where the content moves fastest and where an out-of-date resource is not merely unhelpful but actively wrong. It is also the specialty with the cleanest decision framework, because almost every treatment question in the exam is answered by four variables applied in order. Candidates who work through them systematically find that questions which looked impossibly detailed become tractable. Candidates who reach straight for the regimen find that they have chosen a real drug, used in that cancer, that happens to be wrong for this patient.
Key takeaways
- The exam is two papers of 100 best-of-five questions, three hours each, with a break, and no negative marking.
- Establish four things in order: the stage, the biomarker, the patient's fitness, and the treatment intent.
- Treatment intent is the variable candidates skip, and it determines whether an aggressive answer is right or wrong.
- Performance status and comorbidity are not background: they change what can be offered at all.
- Systemic therapy content dates fast, so check the currency of everything you learn and prefer recent sources.
The four-part framework
Before you look at the options in any treatment question, answer four questions from the stem. In this order.
What is the stage? Localised, locally advanced, or metastatic. This is the first branch and it determines everything downstream, because the treatments and the goals differ entirely.
What is the biomarker status? Increasingly this is the whole question. Receptor status, mutation status, fusion status, expression levels, mismatch repair status. Modern oncology is stratified by these, and a question that supplies one is telling you which therapy is on the table, and, just as importantly, which is not.
How fit is this patient? Performance status, comorbidity, organ function. A regimen that is standard for a fit patient may be undeliverable for this one, and the exam presents that scenario deliberately.
What is the intent? Cure, disease control, or symptom relief. This is the variable candidates omit, and it is the one that most often separates the correct answer from the plausible one.
Why intent is the master variable
Consider what changes when intent changes, holding everything else constant.
If the intent is curative, then toxicity is worth tolerating, dose intensity matters, and completing the treatment as designed is a priority, because the prize is cure. Compromising the regimen to spare side effects may cost the patient their chance.
If the intent is disease control in the metastatic setting, the calculus inverts. The patient will be on treatment for a long time, quality of life is the currency, and the correct answer is frequently the less toxic option, the dose reduction, the treatment break, or the sequential rather than the combination approach.
If the intent is symptom directed, then the tumour is no longer the target. Radiotherapy for a painful bone metastasis, drainage of an effusion, or a referral to palliative care may be the entire answer, and the candidate who offers another line of systemic therapy has misunderstood what is being asked.
The same cancer, the same biomarker, and the same drug list produce three different correct answers depending on which of these three applies. Establish it before you choose.
Performance status is not a formality
Candidates read the performance status, note it, and then answer as though it were not there.
It is one of the strongest determinants of what can be offered. A patient with poor performance status will not tolerate an intensive regimen, will derive less benefit from it, and may be harmed by it, and the correct answer in that situation is frequently best supportive care or a substantially gentler approach.
This is not therapeutic nihilism and the exam is careful about the distinction. It is the recognition that treatment which cannot be delivered, or which will cause more harm than the cancer would in the patient's remaining time, is not treatment. When a vignette gives you a poor performance status, that is the question.
The same applies to organ function. Renal, hepatic and cardiac function determine which agents are usable and at what dose, and questions are routinely constructed around an agent that would be first-line if only this patient's kidneys allowed it.
Date-stamp everything you learn
This warning is specific to oncology and it matters more here than in any other specialty.
Systemic anticancer therapy changes fast. Indications expand, new agents move into earlier lines, biomarker thresholds shift, and a regimen that was standard three years ago may now be second-line or superseded. A revision resource, a textbook, or a question bank that has not been recently updated will teach you, confidently and clearly, something that is no longer true.
Two disciplines follow. Prefer recent material for systemic therapy specifically, and treat any undated resource with suspicion. And when you extract a rule about a treatment sequence, note when you learned it and from where, because in this specialty a rule has a shelf life.
The stable content, the staging principles, the biology, the emergencies, the toxicities, the reasoning framework itself, is where your foundational effort is safest. The moving content requires currency.
Oncological emergencies are their own domain
Treat these separately, because they are examined separately and because they follow acute-medicine reasoning rather than oncology reasoning.
Neutropenic sepsis, which is a time-critical emergency where the answer is almost always immediate empirical antibiotics and not investigation. Spinal cord compression, where delay costs function permanently. Hypercalcaemia. Superior vena cava obstruction. Tumour lysis syndrome and its prophylaxis. Raised intracranial pressure from metastases.
These questions do not reward the four-part framework above. They reward recognising a time-critical emergency and acting, and the commonest error is investigating a patient who needs treating. Practise them as their own block.
Toxicity management is examinable
The final domain candidates under-revise. Modern oncology's toxicities are a specialty in themselves, and the immune-related adverse effects of checkpoint inhibition in particular behave quite unlike classical chemotherapy toxicity: they can affect almost any organ, they can present late, and their management is frequently steroids and drug cessation rather than the supportive care that classical toxicity demands.
Learn the toxicity profile alongside the agent, not afterwards, because the exam presents a patient on a treatment with a new symptom and asks what is happening.
Where iatroX fits
iatroX's Medical Oncology SCE bank is built around the stage, biomarker, fitness and intent framework that this exam actually tests, with explanations grounded in current guidance and content maintained against a specialty that moves faster than any other, which is the specific weakness of stale revision material in oncology. Missed questions can be opened in the Socratic Tutor, which asks you to reason before it explains and names which of the four variables you failed to establish, and spaced repetition returns the emergencies and toxicity profiles that decay. Try it with free sample questions at iatroX. For the whole-patient reasoning that oncology shares with geriatric medicine, see multimorbidity and competing priorities.
Frequently asked questions
What framework should I use for oncology treatment questions? Establish four things in order: the stage, the biomarker status, the patient's fitness, and the treatment intent. Most treatment questions in the exam are decided by these four, and the one candidates skip is intent.
Why does treatment intent matter so much? Because the same cancer with the same biomarker produces different correct answers depending on whether you are aiming for cure, for disease control, or for symptom relief. Toxicity worth tolerating for cure is not worth tolerating for palliation.
How current does my oncology revision material need to be? Very. Systemic therapy changes fast, indications expand and agents move between lines, so an out-of-date resource will teach you something confidently and wrongly. Prefer recent material for systemic therapy and be suspicious of undated resources.
Should I revise oncological emergencies separately? Yes. Neutropenic sepsis, cord compression, hypercalcaemia, tumour lysis and superior vena cava obstruction reward acute-medicine reasoning rather than oncological reasoning, and the commonest error is investigating a patient who needs immediate treatment.